Delivery Order SPE2DB22D2206-SPE2DB25FJV02
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a ceiling value of $14,787.00. This firm fixed-price delivery order, which is set to be completed by August 12, 2025, will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $1,591.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract...
- The Defense Logistics Agency awarded a delivery order valued at $15,801.10 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed-price contract type. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania serves as the place of performance for this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $27,084.93. This is a firm fixed price delivery order with an ultimate completion date of September 4, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $19,111.33 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units). This contract, executed on July 29, 2025, with an ultimate completion date of July 30, 2025, utilizes firm fixed-price pricing and was competitively awarded without any set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $29,840.86 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) under a firm fixed-price contract. The award was made on August 12, 2025, with an ultimate completion date of August 13, 2025, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $17,178.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60 count) on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $39,626.90 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This firm fixed price contract, which is a child order under a larger indefinite delivery vehicle, requires completion by August 28, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $10,308.12 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with a completion date of July 22, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a relatively small transaction within the company's extensive federal pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $30,789.71 on August 4, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 5, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania location. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug Corp's prime...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV02Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $16,915.19 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on September 8, 2025, with completion scheduled for September 9, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and is fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under a larger Indefinite Delivery Contract vehicle. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's substantial federal contract portfolio demonstrates its capability to fulfill federal medical procurement requirements across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.9k | 9/8/25 |